查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1727105

美國的輔助生殖技術醫療(ART)市場:各產品，各技術，患者各類型，各終端用戶，各地區，機會，預測，2018年～2032年

United States Assisted Reproductive Technology Market Assessment, By Product, By Technology, By Patient Type, By End-user, Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 127 Pages | 商品交期: 3-5個工作天內

價格

美國輔助生殖技術 (ART) 市場規模預計將從 2024 年的 62.8 億美元增長至 2032 年的 95.6 億美元，預測期內（2025-2032 年）的複合年增長率為 5.40%。市場成長的推動因素包括：越來越多的人傾向於推遲生育，生活方式和飲食習慣的改變導致不孕症病例增加，以及人們對市場上各種不孕症治療方法的認識不斷提高。根據美國疾病管制與預防中心的估計，約有 13.4% 的 15-49 歲女性患有不孕症。

在美國，同性伴侶數量的增加和單親家庭的日益增長，進一步增加了對 ART 的依賴。卵子捐贈和精子庫已成為公認的第三方生殖方法，而妊娠代孕在美國多個州也獲得了法律和社會的認可。生育診所正在擴大其捐贈庫網路和代孕配對服務，以滿足患者的多樣化需求。然而，由於涉及倫理和法律的複雜性，這些安排也帶來了許多課題。儘管如此，這些領域的透明度正在提高，標準化框架也確保了患者和捐贈者的權益。

本報告提供美國的輔助生殖技術醫療(ART)市場相關調查，提供市場概要，以及產品，各技術，患者各類型，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 美國的輔助生殖技術醫療(ART)市場預測，2018年～2032年

  • 市場規模分析與預測
  • 市場佔有率分析與預測
    • 各產品
      • 設備
      • 消耗品
      • 試劑和培養基
    • 各技術
      • 體外受精(IVF)
      • 人工授精(AI-IUI)
      • 凍結胚移植(FER)
      • 其他
    • 患者各類型
      • 男性
      • 女性
    • 各終端用戶
      • 不孕治療診所
      • 醫院
      • 外科中心
      • 臨床研究機關
      • 其他
    • 各地區
      • 東北部
      • 中西部
      • 西部
      • 南部
    • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
  • 2024年的市場地圖分析

第6章 需求供給分析

第7章 進出口的分析

第8章 價值鏈分析

第9章 波特的五力分析

第10章 大環境分析

第11章 價格分析

第12章 市場動態

  • 市場促進因素
  • 市場課題

第13章 市場趨勢與發展

第14章 法規結構和革新

  • 法規當局的認證

第15章 專利的形勢

第16章 案例研究

第17章 競爭情形

  • 前五名市場領導的競爭矩陣
  • 前五名參與企業的SWOT分析
  • 前10名市場主要企業的形勢
    • CooperSurgical, Inc.
    • Thermo Fisher Scientific Inc.
    • FUJIFILM Irvine Scientific, Inc.
    • Cook Group Incorporated
    • Vitrolife, Inc.
    • Hamilton Thorne Inc.
    • Ferring B.V.
    • Genea Group
    • Esco Lifesciences Group Ltd.
    • Kitazato Corporation

第18章 策略性建議

第19章 關於調查公司·免責聲明

Product Code: MX13143

United States assisted reproductive technology (ART) market is projected to witness a CAGR of 5.40% during the forecast period 2025-2032, growing from USD 6.28 billion in 2024 to USD 9.56 billion in 2032. The market's growth can be attributed to the increasing preference for delaying parenthood, rising cases of infertility due to changing lifestyle and eating habits and increasing awareness about the different fertility solutions available in the market. As per the estimates of the Center for Disease Control and Prevention, approximately 13.4% of women of ages 15-49 have impaired fertility.

The increasing number of same-sex couples, along with increasing preference for single parenthood in the United States, are further propelling the reliance on ART in the country. Egg donation and sperm banking have become accepted practices as third-party reproductive modes, and gestational surrogacy has gained legal and social acceptance in several states across the country. Fertility clinics are expanding their networks of donor banks and surrogate-matching services to accommodate the distinctive requirements of diverse patient populations. The ethical and legal intricacies associated with any of these arrangements, however, do present some challenges; nevertheless, transparency in these areas is on the rise due to the framework of standardization to ensure the protection of both patients and donors alike.

Increasing Investments Boost Market Growth

Investments in ART are enabling the expansion of fertility clinics, improving treatment accessibility, and advancements in medical technologies. Availability of capital supports research and development activities, resulting in higher success rates for artificial insemination and IVF, among other procedures. Additionally, investments also allow fertility clinics to modernize and expand their facilities, allowing them to provide high-quality care to the patient population.

In May 2023, Morgan Health (a JPMorgan Chase & Co. business unit) invested USD 25 million in Kindbody, a leading fertility clinic network, to expand the accessibility of high-quality reproductive healthcare services for employees across the United States to combat the growing threat of infertility.

Technological Advancements Support Market Expansion

Growing emphasis on technological innovations is driving the market's growth and bolstering the availability of technological solutions such as time-lapse embryo imaging, artificial intelligence-assisted embryo selection, non-invasive preimplantation genetic testing (niPGT), and advanced cryopreservation techniques. Artificial intelligence and machine learning tools are becoming increasingly useful in identifying the most viable embryos for implantation, thereby reducing cycle failure rates and improving live birth outcomes. Robot-assisted minimally invasive procedures make egg retrievals and embryo transfer more comfortable for patients and enable faster recovery. These technological improvements are making ART more accessible, efficient, and personalized, thus allowing the market players to expand their customer base.

Additionally, leading ART service providers are also focusing on collaborations to ensure the delivery of advanced technologies and services. For instance, in October 2024, Cryoport, Inc. partnered with TMRW Life Sciences, Inc. to provide fertility clinics with advanced solutions for secure transportation and management of the specimen.

Fertility Clinics Hold Major Market Share

Fertility clinics hold a major share of the market in the United States as they offer a broad range of fertility services, including fertility ART procedures, donor services, and counseling. The specialized workforce, state-of-the-art laboratories, and individual treatment protocols make clinics the preferred option for patients. Many clinics have cooperative agreements and are part of growing fertility networks supported by private equity firms, thus leading to greater consolidation and expansion. Such consolidation allows for greater service scalability, enhanced quality assurance, and regional and national brand marketing, allowing them to expand their market presence. Additionally, various fertility clinics are also focusing on developing digital patient portals, using mobile applications for tracking treatment adherence, and artificial intelligence-based cycle management platforms to make the treatment journey smoother, thus allowing the segment's expansion. Furthermore, various fertility clinics are also focusing on partnerships and collaborations to ensure the provision of advanced treatment solutions to the patient population.

For instance, in April 2024, First Fertility, one of the largest fertility networks in the United States, expanded its nationwide presence by partnering with Fertility & Surgical Associates of California (FSAC), a leading fertility practice known for advanced treatments. The collaboration aims to combine First Fertility's comprehensive, patient-centered care model with FSAC's expertise and advanced technology, enhancing access to state-of-the-art reproductive healthcare in the region.

Impact of the U.S. Tariffs on United States Assisted Reproductive Technology (ART) Market

The recently imposed tariffs have resulted in significant challenges for the ART market in the United States. The tariffs, aimed at boosting domestic manufacturing, have resulted in supply chain disruptions and increased costs for raw materials within the industry.

The tariffs are expected to bolster the costs of essential equipment and consumables for ART, including specialized laboratory equipment, cryopreservation media, and incubators. These increased costs are expected to cause hindrances for small and medium-sized fertility clinics that may struggle to absorb the increased expenses. Thus, affecting the affordability of the treatment solutions, limiting access to ART.

Key Players Landscape and Outlook

The market's key players are focusing on launching next-generation solutions to bolster the effectiveness of reproductive technologies. For instance, in July 2023, Thermo Fisher Scientific Inc. launched the Ion AmpliSeq Polyploidy Kit and the Ion ReproSeq PGT-A Kit for supporting preimplantation genetic testing-aneuploidy (PGT-A), commonly used to inform intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) research. PGT-A testing is used to identify chromosomal abnormalities in embryos. Such launches are expected to enhance the probability of successful pregnancies and improve reproductive health outcomes for future generations by providing researchers with deeper genomic insights.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. United States Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Instruments
        • 5.2.1.1.1. Sperm Separators
        • 5.2.1.1.2. Embryo Incubators
        • 5.2.1.1.3. Cryosystems
        • 5.2.1.1.4. Other Instruments
      • 5.2.1.2. Consumables
        • 5.2.1.2.1. Culture Dishes and Plates
        • 5.2.1.2.2. Storage Vials
        • 5.2.1.2.3. Needles
        • 5.2.1.2.4. Embryo transfer Catheters
        • 5.2.1.2.5. Other Consumables
      • 5.2.1.3. Reagents and Media
        • 5.2.1.3.1. Embryo Culture Media
        • 5.2.1.3.2. Cryopreservation Media
        • 5.2.1.3.3. Semen Processing Media
    • 5.2.2. By Technology
      • 5.2.2.1. In-vitro Fertilization (IVF)
      • 5.2.2.2. Artificial Insemination (AI-IUI)
      • 5.2.2.3. Frozen Embryo Replacement (FER)
      • 5.2.2.4. Other Technologies
    • 5.2.3. By Patient Type
      • 5.2.3.1. Male
      • 5.2.3.2. Female
    • 5.2.4. By End-user
      • 5.2.4.1. Fertility Clinics
      • 5.2.4.2. Hospitals
      • 5.2.4.3. Surgical Centers
      • 5.2.4.4. Clinical Research Institutes
      • 5.2.4.5. Others
    • 5.2.5. By Region
      • 5.2.5.1. Northeast
      • 5.2.5.2. Midwest
      • 5.2.5.3. West
      • 5.2.5.4. South
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Product
    • 5.3.2. By Technology
    • 5.3.3. By Patient Type
    • 5.3.4. By End-user
    • 5.3.5. By Region

6. Demand Supply Analysis

7. Import and Export Analysis

8. Value Chain Analysis

9. Porter's Five Forces Analysis

10. PESTLE Analysis

11. Pricing Analysis

12. Market Dynamics

  • 12.1. Market Drivers
  • 12.2. Market Challenges

13. Market Trends and Developments

14. Regulatory Framework and Innovation

  • 14.1. Regulatory Approvals

15. Patent Landscape

16. Case Studies

17. Competitive Landscape

  • 17.1. Competition Matrix of Top 5 Market Leaders
  • 17.2. SWOT Analysis for Top 5 Players
  • 17.3. Key Players Landscape for Top 10 Market Players
    • 17.3.1. CooperSurgical, Inc.
      • 17.3.1.1. Company Details
      • 17.3.1.2. Key Management Personnel
      • 17.3.1.3. Products and Services
      • 17.3.1.4. Financials (As Reported)
      • 17.3.1.5. Key Market Focus and Geographical Presence
      • 17.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 17.3.2. Thermo Fisher Scientific Inc.
    • 17.3.3. FUJIFILM Irvine Scientific, Inc.
    • 17.3.4. Cook Group Incorporated
    • 17.3.5. Vitrolife, Inc.
    • 17.3.6. Hamilton Thorne Inc.
    • 17.3.7. Ferring B.V.
    • 17.3.8. Genea Group
    • 17.3.9. Esco Lifesciences Group Ltd.
    • 17.3.10. Kitazato Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

18. Strategic Recommendations

19. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. United States Assisted Reproductive Technology (ART) Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. United States Assisted Reproductive Technology (ART) Market Share (%), By Product, 2018-2032F
  • Figure 3. United States Assisted Reproductive Technology (ART) Market Share (%), By Technology, 2018-2032F
  • Figure 4. United States Assisted Reproductive Technology (ART) Market Share (%), By Patient Type, 2018-2032F
  • Figure 5. United States Assisted Reproductive Technology (ART) Market Share (%), By End-User, 2018-2032F
  • Figure 6. United States Assisted Reproductive Technology (ART) Market Share (%), By Region, 2018-2032F
  • Figure 7. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 8. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 9. By Patient Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 10. By End-User Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024